OREXIN A - Research Grade Peptide

OREXIN A – Research-Grade 33-Residue Peptide

For research purposes only. This product is supplied exclusively for scientific laboratory research and analytical purposes. It is not intended for human or animal use, consumption, clinical use or therapeutic application. It must not be used in any way that contravenes applicable laws or the requirements of the Medicines and Healthcare products Regulatory Agency.

• Research-grade Orexin A peptide with batch documentation available where supplied
• Defined mature peptide sequence comprising 33 amino-acid residues
• N-terminal pyroglutamate, C-terminal amide and two defined intramolecular disulphide bridges
• Supplied as lyophilised laboratory material in sealed flip-top headspace vials
• Batch identity, chromatographic purity, peptide content and analytical specifications stated in the applicable Certificate of Analysis
• Handled and supplied exclusively as a research-use laboratory material

All of our research peptides and related laboratory materials are supplied strictly for scientific research and laboratory use only. Each vial contains lyophilised material prepared to support controlled laboratory handling and storage. The stated nominal amount refers to the declared Orexin A peptide content of a single vial, subject to the applicable batch documentation. Where dissolution or reconstitution is required, the solvent, buffer, concentration, handling procedure and storage conditions stated in the applicable Certificate of Analysis, Safety Data Sheet or validated laboratory method should be followed. We do not provide advice or recommendations concerning dosage, administration or use in humans or animals.

Chemical and Structural Information:

• Product Name: OREXIN A
• Preferred Technical Name: Orexin-A
• Alternative Names: Hypocretin-1; HCRT-1; Hcrt1; Orexin A
• Material Classification: Sequence-defined 33-residue peptide
• Sequence Length: 33 amino-acid residues
• Complete Modified Peptide Sequence: pGlu-Pro-Leu-Pro-Asp-Cys-Cys-Arg-Gln-Lys-Thr-Cys-Ser-Cys-Arg-Leu-Tyr-Glu-Leu-Leu-His-Gly-Ala-Gly-Asn-His-Ala-Ala-Gly-Ile-Leu-Thr-Leu-NH₂
• Modified Sequence Shorthand: pGlu-PLPDCCRQKTCSCRLYELLHGAGNHAAGILTL-NH₂
• Unmodified Precursor-Encoded Sequence: Gln-Pro-Leu-Pro-Asp-Cys-Cys-Arg-Gln-Lys-Thr-Cys-Ser-Cys-Arg-Leu-Tyr-Glu-Leu-Leu-His-Gly-Ala-Gly-Asn-His-Ala-Ala-Gly-Ile-Leu-Thr-Leu
• Human Precursor Reference: Corresponds to residues 34–66 of the human hypocretin neuropeptide precursor, UniProt accession O43612
• N-Terminal Structure: Pyroglutamate formed by cyclisation of the precursor-encoded N-terminal glutamine residue
• C-Terminal Structure: C-terminal leucinamide
• Disulphide-Bond Connectivity: Cys⁶–Cys¹² and Cys⁷–Cys¹⁴
• Total Disulphide Bonds: Two intramolecular disulphide bridges
• CAS Number: 205640-90-0
• PubChem Compound Identifier: CID 56842143
• Molecular Formula: C₁₅₂H₂₄₃N₄₇O₄₄S₄
• Average Molecular Weight: Approximately 3561.1 g/mol
• Approximate Molecular Size: 3.56 kDa
• Formula Basis: The molecular formula and molecular weight describe the mature peptide with its N-terminal pyroglutamate, C-terminal amide and two intramolecular disulphide bonds, without additional counter-ions, residual water or formulation excipients
• Physical Form: Lyophilised laboratory material, as stated in the applicable batch Certificate of Analysis
• Appearance: White to off-white laboratory material, subject to confirmation in the applicable batch Certificate of Analysis
• Purity Specification: The applicable chromatographic purity result, analytical method and acceptance criterion are stated in the batch Certificate of Analysis
• Peptide-Content Specification: Net Orexin A peptide content should be distinguished from chromatographic purity and interpreted alongside water, counter-ion, residual-solvent and formulation results
• Sequence Confirmation: The complete 33-residue sequence should be confirmed using the applicable synthesis, supplier and batch records
• N-Terminal Modification Confirmation: The N-terminal pyroglutamate should be supported by appropriate molecular-identity or mass-spectrometry documentation
• C-Terminal Modification Confirmation: The C-terminal leucinamide should be distinguished from a free carboxylic acid terminal structure
• Disulphide-Connectivity Confirmation: Correct Cys⁶–Cys¹² and Cys⁷–Cys¹⁴ connectivity is a distinct structural quality attribute and is not established by chromatographic purity alone
• Mass-Spectrometry Confirmation: Molecular identity should be supported by analytical mass data consistent with the mature Orexin A molecular structure
• Chemical-Form Confirmation: The applicable Certificate of Analysis should identify whether the supplied laboratory material is the uncountered peptide, an acetate form, a trifluoroacetate form or another counter-ion form
• Counter-Ion Confirmation: Acetate, trifluoroacetate or another counter-ion may affect the total measured material mass and net peptide content of the supplied laboratory material
• Residual-Solvent Specification: Applicable residual solvents arising from peptide synthesis, cleavage, disulphide formation and chromatographic purification should be stated or controlled through the batch specification
• Related-Impurity Control: Deletion sequences, truncated peptides, incompletely modified termini, reduced peptide, incorrectly paired disulphide species and other peptide-related or process-related impurities are separate quality attributes
• Endotoxin Specification: The applicable bacterial endotoxin or lipopolysaccharide result, analytical method, reporting units, method-suitability controls and acceptance criterion should be stated in the batch Certificate of Analysis
• Analytical Interpretation: Molecular identity, amino-acid sequence, terminal modifications, disulphide connectivity, chromatographic purity, net peptide content, water content, residual solvents, counter-ion content and bacterial endotoxin results are separate analytical measurements and should be interpreted together

✓ Batch documentation – Completed Certificate of Analysis documentation is provided where supplied for the applicable batch.
✓ Certificate of Analysis – Accessible through the product QR code where a completed batch-specific document has been published.
✓ Safety Data Sheet – Supplied to support appropriate laboratory handling, storage and regulatory compliance.
✓ Sequence documentation – The complete 33-residue Orexin A amino-acid sequence should be confirmed using the applicable batch and synthesis records.
✓ Terminal-modification documentation – N-terminal pyroglutamate and C-terminal amidation should be supported by appropriate molecular-identity data.
✓ Disulphide-bond documentation – Formation of the two intended intramolecular disulphide bridges should be supported by appropriate structural, production or analytical records.
✓ Mass-spectrometry documentation – Molecular identity should be supported by analytical mass data consistent with the specified Orexin A molecular structure.
✓ Purity documentation – The reported chromatographic purity applies only to the analytical method and batch stated in the Certificate of Analysis.
✓ Peptide-content documentation – Net Orexin A peptide content should be distinguished from chromatographic purity and interpreted alongside water, counter-ion and residual-solvent results.
✓ Chemical-form documentation – The uncountered peptide, acetate form, trifluoroacetate form or other counter-ion form should be identified clearly in the applicable product and batch records.
✓ Bacterial endotoxin documentation – The applicable bacterial endotoxin or lipopolysaccharide result should identify the test method, reporting units, method-suitability controls and acceptance criterion.
✓ Supplier documentation – Reviewed where supporting synthesis, disulphide formation, purification and analytical records are supplied.
✓ Fast, reliable and trackable express delivery – Securely packaged and dispatched using insulated or temperature-managed packaging where required by the applicable transport and storage specification.

For Research Use Only
This product is supplied strictly for scientific research, laboratory analysis and experimental work. It is not intended for human consumption, animal use, clinical use, diagnostic use or any form of therapeutic application.

Orexin A Product Overview

Our Orexin A research-grade 33-residue peptide, also known as Hypocretin-1, is supplied for controlled scientific laboratory investigation, analytical method development, peptide characterisation, high-performance liquid chromatography assessment, mass-spectrometry workflows and reference-material comparison.

The mature Orexin A structure comprises a defined sequence of 33 amino-acid residues containing an N-terminal pyroglutamate, a C-terminal amide and two intramolecular disulphide bridges. The specified disulphide connectivity is Cys⁶–Cys¹² and Cys⁷–Cys¹⁴.

The material is handled with a focus on batch traceability, documented quality control and consistent laboratory presentation. Product identity, amino-acid sequence, terminal modifications, chromatographic purity, net peptide content, disulphide-bond connectivity, molecular form, counter-ion content, water content, residual solvents, bacterial endotoxin results and other analytical specifications should be confirmed using the applicable batch Certificate of Analysis.

The CAS number 205640-90-0, molecular formula C₁₅₂H₂₄₃N₄₇O₄₄S₄ and average molecular weight of approximately 3561.1 g/mol describe the mature, uncountered Orexin A molecular structure. Where the supplied laboratory material contains acetate, trifluoroacetate or another counter-ion, the applicable batch documentation should identify its contribution to the total material mass.

Chromatographic purity should not automatically be interpreted as equivalent to total net peptide content. Likewise, a bacterial endotoxin or lipopolysaccharide result does not establish sterility, correct disulphide connectivity, molecular identity, terminal-modification integrity or the absence of every peptide-related and process-related impurity.

For the majority of routine analytical, chromatographic, peptide-characterisation and general laboratory work, the Regular Orexin A specification remains highly suitable. The premium black-and-gold ULTIMATE Orexin A option provides an additional preparative high-performance liquid chromatography purification stage and a more stringent bacterial endotoxin and lipopolysaccharide testing specification for scientific projects requiring enhanced quality-control parameters.

View Certificate of Analysis

View Safety Data Sheet